2015-07-20 13:34 ET - News Release
Mr. Dan Legault reports
THERAPEUTICS ANNOUNCES ADDITION OF ASPIRIN DERIVATIVE TO ITS PRODUCT
PIPELINE AND PROVIDES AN UPDATE ON VALIDATION STUDIES
Antibe Therapeutics Inc. has added ATB-340, a
hydrogen-sulphide-releasing derivative of aspirin, to its product pipeline.
After more than 100 years on the market, aspirin remains among the most
widely used drugs, with annual sales of approximately $2-billion and over 6-per-cent growth.
Originally marketed as a treatment for pain and fever, the uses of
aspirin have grown to include prevention of blood clotting in patients
at risk of heart attacks and strokes, as well as prevention of certain types of
cancer. The major side effect of aspirin is gastrointestinal bleeding,
which can be life threatening. Aspirin produces its beneficial
cardiovascular effects by blocking the activity of an enzyme (called
cyclooxygenase (COX)) that produces substances that promote blood
platelets to aggregate (an important part of blood clotting). This
effect can be achieved by taking low doses of aspirin on a daily basis.
However, even at these low doses, the adverse effects of aspirin in the
stomach and intestines are still evident and potentially serious.
ATB-340 is being developed with the objective of eliminating these
In preclinical studies, ATB-340 has been shown to be at least as potent
as aspirin in blocking the COX enzyme and reducing blood clotting.
However, while aspirin produced significant stomach and intestinal
ulceration and bleeding in rats, ATB-340 did not. In human blood,
ATB-340 inhibited platelet aggregation as effectively as aspirin.
Antibe would also like to advise the market that the previously
announced validation studies on its lead drug, ATB-346, remain on
schedule. These studies, which involve use of radioactively labelled
ATB-346, track the metabolism and excretion of the drug. Antibe
anticipates results from these studies during the fourth quarter.
In parallel, Antibe continues to investigate additional partnering and